Biostatistics, Epidemiology & Environmental Health Sciences: Faculty Publications

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I)

Document Type

Article

Publication Date

3-31-2020

Publication Title

LinkedIn

Abstract

It is well-recognized that the COVID-19 pandemic has hit many ongoing clinical trials hard in many ways, including but not limited to:

  1. Government interventions including suppression and non-pharmaceutical interventions (NPIs) such as social distancing, lockdown, or quarantine.
  2. Supplies of study medications and availability of healthcare professionals and facilities for clinical and/or laboratory evaluations, treatment administration according to scheduled clinical visits typically specified in Table 1 of study protocols.

Copyright

This work is archived and distributed under the repository's Standard Copyright and Reuse License (opens in new tab). End users may copy, store, and distribute this work without restriction. For all other uses, permission must be obtained from the copyright owners or their authorized agents.

Link to Full Text

Share

COinS